Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4301-4310 Newer>

The Motley Fool November 2, 2007 Brian Lawler	Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note.
The Motley Fool November 2, 2007 Billy Fisher	Successful Transitions at Molina The managed-care provider gets rid of what isn't working and builds upon what is.
The Motley Fool November 2, 2007 Brian Lawler	A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note.
CFO November 1, 2007 Lori Calabro	Bitter Medicine New anti-counterfeiting laws are costing drug companies a fortune.
The Motley Fool November 1, 2007 Brian Orelli	Good News From Amylin Isn't Good Enough Investors aren't impressed by Amylin's extended-release version of Byetta, worrying that the drug may be reaching market saturation.
The Motley Fool November 1, 2007 Brian Orelli	More Extrinsic Growth From Inverness on the Way Comparing year-over-year gains at Inverness Medical Innovations is becoming harder with each passing press release announcing the purchase of another company.
The Motley Fool November 1, 2007 Brian Lawler	Achtung, GPC! The German biotech sector took a hit yesterday, after GPC Biotech and partner Pharmion announced that GPC's lead drug, satraplatin, had failed an important endpoint in phase 3 testing.
Chemistry World October 31, 2007 James Mitchell Crow	Firms Unprepared as First Reach Deadline Looms Firms must act now if they are to hit the November 2008 deadline to pre-register a substance under Reach, the new European chemicals legislation.
The Motley Fool October 31, 2007 Brian Orelli	A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note.
The Motley Fool October 31, 2007 Brian Lawler	Adams On-and-Off With the FDA A new compound gets delayed, but the drugmaker still raises earnings guidance, and shares rise. Investors, take note.
<Older 4301-4310 Newer> Return to current articles.